Literature DB >> 9688948

Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax.

S R Narasimhan1, L Yang, B I Gerwin, V C Broaddus.   

Abstract

A failure of normal apoptosis, often due to mutant p53, may contribute to the formation of a cancer and to its resistance to therapy. Mesothelioma, an asbestos-induced tumor, is highly resistant to therapy but generally expresses wild-type p53. We asked whether mesothelioma was resistant to apoptosis and whether resistance was associated with altered expression of the antiapoptotic protein Bcl-2 or proapoptotic protein Bax. We found that three mesothelioma cell lines (1 with wild-type p53) were highly resistant to apoptosis induced by oxidant stimuli (asbestos, H2O2) or nonoxidant stimuli (calcium ionophore) compared with primary cultured mesothelial cells. By immunostaining, one of these three lines expressed Bcl-2 but only during mitosis. By immunoblotting, 3 of 14 additional mesothelioma lines (9 of 14 with wild type p53) expressed Bcl-2 but all 14 of 14 expressed the proapoptotic Bax, giving a low ratio of Bcl-2 to Bax. We conclude that mesothelioma cell lines are resistant to apoptosis and that the failure in apoptosis is not explained by Bcl-2 but by other mechanisms that counteract the proapoptotic effect of Bax.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688948     DOI: 10.1152/ajplung.1998.275.1.L165

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  16 in total

Review 1.  The molecular basis of asbestos induced lung injury.

Authors:  D W Kamp; S A Weitzman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

2.  Destruction of gastric cancer cells to mesothelial cells by apoptosis in the early peritoneal metastasis.

Authors:  Di Na; Funan Liu; Zhifeng Miao; Zongmin Du; Huimian Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

Review 3.  Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases.

Authors:  Sarah X L Huang; Marie-Claude Jaurand; David W Kamp; John Whysner; Tom K Hei
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

4.  MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces apoptosis in malignant pleural mesothelioma cells.

Authors:  Nazli Khodayari; Kamal A Mohammed; Hungyen Lee; Frederick Kaye; Najmunnisa Nasreen
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

5.  Curcumin induces apoptosis in breast cancer cells and inhibits tumor growth in vitro and in vivo.

Authors:  Zhi-Dong Lv; Xiang-Ping Liu; Wei-Jun Zhao; Qian Dong; Fu-Nian Li; Hai-Bo Wang; Bin Kong
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

6.  Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.

Authors:  Feng An; Daryl C Drummond; Shannon Wilson; Dmitri B Kirpotin; Stephen L Nishimura; V Courtney Broaddus; Bin Liu
Journal:  Mol Cancer Ther       Date:  2008-03-04       Impact factor: 6.261

Review 7.  Current therapy for malignant mesothelioma.

Authors:  W Roy Smythe
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.945

8.  The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.

Authors:  Xinran Xiang; Yen Phung; Mingqian Feng; Kunio Nagashima; Jingli Zhang; V Courtney Broaddus; Raffit Hassan; David Fitzgerald; Mitchell Ho
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

9.  Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.

Authors:  Dario Barbone; Priscilla Cheung; Sailaja Battula; Sara Busacca; Steven G Gray; Daniel B Longley; Raphael Bueno; David J Sugarbaker; Dean A Fennell; V Courtney Broaddus
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

10.  Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells.

Authors:  M Tomasetti; M R Rippo; R Alleva; S Moretti; L Andera; J Neuzil; A Procopio
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.